Zydus Lifesciences gains as company launches world’s first Nivolumab biosimilar in India
News by Aliceblue News Desk
22 Jan 2026
Introduction
Leading life-sciences company launches India’s first Nivolumab biosimilar, Tishtha™, providing affordable advanced Immuno-Oncology treatment in 100 mg and 40 mg dosages for cancer patients.
Also Read: Stallion India Fluorochemicals stock in focus after RIICO allots industrial plot for R-32 plant
Share price movement of Zydus Lifesciences
On January 22, 2026, Zydus Lifesciences Ltd opened at ₹879.95, up 0.44% from its previous close of ₹876.10. The stock reached a high of ₹888.25 (1.38%) and a low of ₹876.55. By 3:00 PM, it traded at ₹885.45, a 1.07% increase, with a market cap of ₹89,086.93 crore.
Zydus Launches Nivolumab Biosimilar Tishtha™
Zydus Lifesciences Limited has launched India’s first biosimilar of Nivolumab, branded as Tishtha™, to treat multiple cancers. The launch strengthens the company’s advanced biologics and Immuno-Oncology portfolio.
Tishtha™ will be available in 100 mg and 40 mg dosages, priced at ₹28,950 and ₹13,950 respectively, approximately one-fourth the cost of the reference drug, improving affordability for patients.
The biosimilar is developed and manufactured in India to ensure consistent availability. The two-strength portfolio allows oncologists to optimize dosing, minimize wastage, and support uninterrupted treatment for over five lakh patients.
Stock performance of Zydus Lifesciences for Period of 1 week, 6 months, and 1 year
Zydus Lifesciences Ltd fell 0.85% over the past week, declined 10.3% in the past 6 months, and dropped 10.4% over the past 1 year.
Also Read: JSW Energy stock gains as arm signs PPA for 1,600 MW thermal project in West Bengal
Shareholding pattern of Zydus Lifesciences
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 75.00% | 75.00% | 75.00% |
| FII | 7.10% | 7.30% | 7.10% |
| DII | 11% | 11% | 11% |
| Public | 7% | 7% | 7% |
About Zydus Lifesciences
Zydus Lifesciences Ltd (NSE: ZYDUSLIFE), formed from Cadila Healthcare in 1995, focuses on healthcare innovation, global growth, and creating healthier communities through pharmaceutical and life-sciences solutions.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Zydus Lifesciences Ltd share price rising today?
A: Zydus Lifesciences launches Tishtha™, India’s first Nivolumab biosimilar, providing advanced cancer treatment at one-fourth the reference drug cost.
Q: What is Zydus Lifesciences Ltd’s main business focus?
A: Zydus Lifesciences Ltd focuses on pharmaceuticals, biologics, and healthcare innovation, addressing unmet medical needs and creating healthier communities globally.
Q: What is the 52-week high and low of Zydus Lifesciences Ltd stock?
A: Zydus Lifesciences Ltd has a 52-week high of ₹1,059.00 and a 52-week low of ₹797.05.
News Author
Aliceblue News Desk
